TENX
Tenax Therapeutics, Inc.
$15.98
-1.57 (-8.95%)
At close · Jul 13
Market Cap
$423.87M
Shares
26,525,159
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$52.6M
-198.8%
FY2025
Gross Margin
0%
+65.5pp
FY2015
Operating Margin
-30062.78%
-19610.7pp
FY2015
Diluted EPS
-$1.34
-16.5%
FY2025
Operating Cash Flow
-$35.8M
-141.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | — | — | — | — | — | — | — | $0 | $49.29K | $158.93K | $1.67M | $475.3K | |
| $4443 | — | — | — | — | $949 | $1627 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | $129.8K | $352.58K | $309.47K | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$104.07K | $210.36K | $160.79K | |
| — | — | — | — | — | — | — | — | — | — | — | 0% | -65.48% | 12.62% | 33.83% | |
| $38.53M | $32.67M | $12.71M | $3.23M | $5.38M | $25.15M | $4.56M | $3.47M | $1.24M | $3.53M | $13.14M | $6.66M | $3M | $24.53M | $22.08M | |
| $23.09M | $23.71M | $6.79M | $5.01M | $5.68M | $7.58M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $7.58M | $5.31M | $5.08M | $5.65M | $5.68M | $6.25M | $7.17M | $13.77M | $50.59M | $46.91M | |
| $0 | — | — | — | — | — | — | — | — | — | $0 | $70.3K | $62.19K | $55.85K | — | |
| — | — | $0 | $8000 | $5143 | $4116 | $4077 | $5017 | $9016 | $13.62K | $18.95K | $148.14K | $150.49K | $2.22M | $2.07M | |
| — | — | — | — | — | — | — | — | — | — | — | $220.72K | $220.72K | $220.72K | — | |
| $61.62M | $56.39M | $19.49M | $8.23M | $11.05M | $32.73M | $9.87M | $8.56M | $6.89M | $9.21M | $52.65M | $14.87M | $16.77M | $75.73M | $69.35M | |
| -$61.62M | -$56.39M | -$19.49M | -$8.23M | $11.05M | -$32.73M | $9.87M | -$8.56M | -$6.89M | -$9.21M | -$52.65M | -$14.82M | -$16.61M | -$74.06M | $68.87M | |
| — | — | — | — | — | — | — | — | — | — | — | -30062.78% | -10452.11% | -4444.87% | 14490.35% | |
| — | — | -$19.49M | -$8.23M | $11.06M | -$32.72M | $9.87M | -$8.55M | -$6.88M | -$9.19M | -$52.63M | -$14.67M | -$16.46M | -$71.84M | $70.94M | |
| — | $0 | $23K | $24K | $4443 | $949 | $1627 | $0 | — | — | $0 | $49.08K | $2.21M | $43.96M | -$39.72M | |
| -$37K | -$33K | $1000 | $63K | -$9191 | — | $18.17K | $160.9K | $79.84K | $366.22K | $764.74K | $784.01K | -$718.44K | $1.23M | -$1.22M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$7.96M | $0 | — | — | — | |
| -$57.91M | -$52.6M | -$17.6M | -$7.71M | $11.05M | -$32.47M | -$9.85M | -$8.39M | -$14.14M | -$8.84M | -$43.92M | -$14.08M | -$19.54M | -$117.39M | $107.63M | |
| — | — | — | — | — | — | — | — | — | — | — | -28571.63% | -12296.19% | -7045.5% | 22644.24% | |
| — | — | — | — | — | — | — | — | — | — | $43.92M | $14.08M | $25.35M | $118M | — | |
| — | — | — | $7.71M | $11.05M | -$32.47M | $9.85M | $8.39M | $14.13M | $8.84M | $43.81M | $14.06M | — | — | — | |
| USD/shares | — | -$1.34 | -$1.15 | -$31.04 | — | — | — | — | — | — | — | -$800.00 | -$4,336.00 | -$10,064.00 | -$976.00 |
| USD/shares | — | -$1.34 | -$1.15 | -$31.04 | — | — | — | — | — | — | — | -$800.00 | -$4,336.00 | -$10,688.00 | -$1,120.00 |
| shares | — | 39.22M | 15.27M | 248.45K | — | 12.86K | 6478.6413 | 3872.1525 | 977.9831 | 881.6438 | 878.745 | 17.55K | 5851.2694 | 1031.425 | 16.21K |
| shares | — | 39.22M | 15.27M | 248.45K | — | 12.86K | 6478.6413 | 3872.1525 | 977.9831 | 881.6438 | 878.745 | 17.55K | 5851.2694 | 1099.3906 | 17.35K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.34×
EV/EBIT
—
Biotechnology median 25.50×
P/E (TTM)
—
Biotechnology median 7.72×